Menu Back toSpeakers

3rd ICH Information Day


Speakers

  • Martin  Harvey Allchurch, LLM

    Martin Harvey Allchurch, LLM

    • Principal International Affairs Officer
    • European Medicines Agency, European Union, United Kingdom

    Law degrees from University of Dundee, UK, and Vrije Universiteit Brussel, Belgium. European affairs consultant in Brussels from 1992 to 1995. Joined EMA legal team in September 1995. Headed the Office of the Executive Director from 2004 to 2012. Appointed Head of Communciation in February 2012, and moved to the Agency's International Affairs team in November 2014. Programme Advisor for DIA Annual Meeting and EuroMeeting and member of DIA Advisory Council for Europe, Middle East and Africa.

  • Lenita  Lindström Gommers

    Lenita Lindström Gommers

    • ICH Assembly Chair and Senior Expert, European Commission
    • European Commission, Belgium

  • Tomas  Salmonson, PhD

    Tomas Salmonson, PhD

    • EMA CHMP Chair; Senior Assessor
    • Swedish Medicines Agency, Sweden

    Tomas Salmonson, M.Sc., PhD, brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency in Uppsala, Sweden. He has been a member of the Committee for Medicinal Products for Human Use (CHMP) for more than 12 years. In 2012, Dr Salmonson was elected chair of the CHMP; he was Vice chair of the CHMP from 2007 till 2012. Tomas has been DIA Advisory Council of Europe Member during 1996-2002 and a speaker in over 20 DIA Events.

  • Toshiyoshi  Tominaga, PhD

    Toshiyoshi Tominaga, PhD

    • Associate Executive Director (for International Programs)
    • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Dr. Tominaga is Associate Executive Director for International Programs. He supervises the overall strategy and conduct of international operations by PMDA. He joined MHLW after acquired PhD from Faculty of Pharmaceutical Sciences, the University of Tokyo. As a career official, he experienced positions dealing with narcotics control, R&D enhancement, and so on. His international experience includes graduate study at Harvard School of Public Health, stay in Vienna as a diplomat, and at USFDA.

  • Steven  Teerenstra, PhD, MSc

    Steven Teerenstra, PhD, MSc

    • Statistician
    • Medicines Evaluation Board, Netherlands

  • Corina Dana Dota, MD

    Corina Dana Dota, MD

    • AZ ECG Centre Director
    • AstraZeneca R&D Molndal, Sweden

  • Jan Willem  van der Laan, PhD

    Jan Willem van der Laan, PhD

    • Senior Assessor Pharmacology and Toxicology
    • Medicines Evaluation Board, Netherlands

    Jan Willem van der Laan is senior pharm-tox assessor of the Medicines Evaluation Board since 1980, and involved in Vaccine assessment for a long period. He contributed to the EU Guideline on Nonclinical testing of Vaccines in 1995, and was involved in several WHO Guidelines on vaccines.

  • Filip  Mussen, PhD

    Filip Mussen, PhD

    • Vice President, Regional Regulatory Affairs
    • Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium

    Filip Mussen is Vice President, Regional Regulatory Affairs at Janssen R&D and responsible for regulatory affairs in Asia-Pacific, Europe, Middle East, Africa, and Latin-America. Filip joined Johnson & Johnson in 2008. In 2011 he became the Head of the Global Labeling CoE. Previously he worked at Merck & Co. in Regulatory Affairs. Filip obtained a Master of Science degree from the University of Gent (Belgium), and his PhD from Cardiff University (UK).

  • Dawn  Ronan

    Dawn Ronan

    • Regulatory & Scientific Manager
    • ICH Secretariat, Switzerland

Contact us


Registration Questions

Send Email
+41 61 225 51 51


Agenda and Logistics

Send Email
+41 61 225 51 65